China: OrbiMed leads $30m Series C in biopharma firm Zai Lab

Visual from Pixabay

US-based healthcare fund management firm OrbiMed led a $30 million Series C preferred equity financing round in Zai Lab Ltd, a bio-pharmaceutical company in Shanghai, China.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.